[{"address1": "1450 North Mcdowell Boulevard", "address2": "Suite 150", "city": "Petaluma", "state": "CA", "zip": "94954", "country": "United States", "phone": "415 578 9583", "website": "https://retinalgenix.com", "industry": "Medical Devices", "sector": "Healthcare", "longBusinessSummary": "RetinalGeniX Technologies Inc., an ophthalmic research and development company, focuses on developing solutions to screen, monitor, diagnose, and treat ophthalmic, optical, and sight-threatening disorders. Its products include the Retinal Imaging Screening Device, a portable retinal imaging system providing a wide field of view without requiring pupil dilation; and RetinalCam, an in-home/remote location patient-activated monitoring and imaging device offering real-time communication and alerting system for physicians. It also develops RTG-2023 for the treatment of dry age-related macular degeneration; and RTG-2024 for the treatment of Alzheimer's syndrome dementia. The company was incorporated in 2017 and is based in Petaluma, California. RetinalGenix Technologies Inc. is a subsidiary of Sanovas Ophthalmology, LLC.", "companyOfficers": [{"maxAge": 1, "name": "Dr. Jerry  Katzman", "age": 70, "title": "CEO, President & Chairman", "yearBorn": 1953, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Virender K. Ahluwalia M.B.A.", "age": 65, "title": "Interim Chief Financial Officer", "yearBorn": 1958, "exercisedValue": 0, "unexercisedValue": 0}], "maxAge": 86400, "priceHint": 4, "open": 3.5, "dayLow": 3.5, "dayHigh": 3.5, "regularMarketOpen": 3.5, "regularMarketDayLow": 3.5, "regularMarketDayHigh": 3.5, "beta": -2.724, "volume": 451, "regularMarketVolume": 451, "marketCap": 62986000, "fiftyTwoWeekLow": 3.0, "fiftyTwoWeekHigh": 9.0, "fiftyDayAverage": 3.5, "twoHundredDayAverage": 3.3765, "trailingAnnualDividendYield": "NaN", "currency": "USD", "enterpriseValue": 63491264, "floatShares": 5544758, "sharesOutstanding": 17996000, "heldPercentInsiders": 0.69715, "bookValue": -0.101, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -4037612, "trailingEps": -0.21, "enterpriseToEbitda": -15.74, "exchange": "OQB", "quoteType": "EQUITY", "symbol": "RTGN", "underlyingSymbol": "RTGN", "shortName": "RETINALGENIX TECHNOLOGIES INC", "longName": "RetinalGenix Technologies Inc.", "firstTradeDateEpochUtc": 1645713000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "e1583bb2-84ff-3065-8095-57c75ac45b00", "gmtOffSetMilliseconds": -14400000, "currentPrice": 3.5, "recommendationKey": "none", "totalCash": 86913, "totalCashPerShare": 0.005, "ebitda": -4033672, "totalDebt": 592061, "quickRatio": 0.046, "currentRatio": 0.046, "returnOnAssets": -56.566402, "freeCashflow": -284022, "operatingCashflow": -455616, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]